By Michelle Calhoun, AbbVie Contract Manufacturing
By all accounts, the current biologics development pipeline is healthy and R&D investment continues to drive growth in novel antibody development. Near-term forecasts indicate a growth rate so robust that it may continue to outpace contract manufacturing capacity. Contributing further is pressure to supply chains to address the increasing requirements for complex molecules such as antibody drug conjugates (ADCs) and bispecific antibodies. This article will explore both market drivers.
Recent trends reported by Future Market Insights (FMI) support the notion that: